Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Bio-Gene Technology Ltd. ( (AU:BGT) ) just unveiled an announcement.
Bio-Gene Technology has secured allowance from the United States Patent and Trademark Office for a key patent covering the synergistic use of its Flavocide insecticide with permethrin or pyrethrin. Formal grant is expected within two to four months, extending U.S. patent protection for this combination to 2040 and reinforcing the company’s IP position around its lead technology.
The patent adds to existing protection for these insecticide combinations in Australia, Japan, New Zealand and 22 African Regional IP Organisation member states, with further territories under review. The expanded patent portfolio strengthens Bio-Gene’s ability to license its technology to commercial partners, potentially enhancing the commercial value and global reach of its next‑generation insecticide solutions.
More about Bio-Gene Technology Ltd.
Bio-Gene Technology Ltd. is an Australian life sciences company developing novel bio‑insecticides to tackle global insecticide resistance. Its products, including Flavocide and Qcide, are based on naturally occurring compounds designed to control pests with minimal impact on human health and the environment, targeting crop protection, grain storage, public health and consumer markets.
Average Trading Volume: 117,216
Technical Sentiment Signal: Buy
Current Market Cap: A$11.59M
Learn more about BGT stock on TipRanks’ Stock Analysis page.